₹49.34 Crores | Listing at BSE | Tue, May 2, 2023 - Wed, May 31, 2023
Earum Pharmaceuticals Limited Rights Issue comprises 24.67 Cr equity shares aggregating to ₹49.34 Cr, offered at an issue price of ₹2 per share with a face value of ₹2 per share.
The record date for determining eligible shareholders is Apr 10, 2023.
As per the terms of payment, ₹2 per share payable on application, with the balance payable in call(s).
The Rights Entitlements are expected to be credited to eligible demat accounts on Apr 26, 2023.
The Rights Issue opens on May 2, 2023 and closes on May 31, 2023.
The deemed date of allotment is Jun 20, 2023, following which the equity shares are expected to be credited to demat accounts on Jun 21, 2023 and listed on the BSE on Jun 26, 2023.
Axis Bank Ltd. is the Lead Manager to the issue and Bigshare Services Pvt.Ltd. is the Registrar to the Issue.
Investors are advised to refer to the Earum Pharmaceuticals Limited Letter of Offer for detailed information, including risk factors, issue terms, and procedural details.
Record Date
Mon, Apr 10, 2023
Entitlement Ratio
:
Open Date
Tue, May 2, 2023
Close Date
Wed, May 31, 2023
| Period Ended | Total Assets | Total Revenue | Profit After Tax | Reserves and Surplus |
|---|---|---|---|---|
| 31-Mar-20 | 36.16 | 57.38 | 1.82 | 8.25 |
| 31-Mar-21 | 27.87 | 50.02 | 0.09 | 8.33 |
| 31-Mar-22 | 28.79 | 28.74 | 2.22 | 4.39 |
| Amount in ₹ Crore | ||||
Incorporated in 2012, Earum Pharmaceuticals Limited is engaged in the pharmaceutical business involving marketing, trading, and distribution of pharmaceutical formulation products.
Earum Pharmaceuticals' product range includes anti-biotic drugs, anti-malarial drugs, anti-allergic & anti-cold drugs, analgesic/antipyretic & anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastrointestinal drugs, steroids, gynecology drugs, calcium, multivitamins, anti-oxidants, and injections.
Currently, the company has its presence in Indian States such as Gujarat, Maharashtra, Chhattisgarh, Uttar Pradesh, Mizoram, Andhra Pradesh, Rajasthan, Madhya Pradesh, Manipur, Assam, Meghalaya, Kerala, Telangana, etc., and intends to penetrate international markets as well.
The company intends to utilize the net proceeds from the issue towards the funding of the following objects:
[Dilip Davda] The company is in the business of trading and marketing of pharmaceutical products. It has marked inconsistency in its top and bottom lines. The five-fold rise in post-RI equity may pose servicing issue. There is no promoter’s holding in this company and vested interests are managing the counter above the RI price to lure investors. There is no harm in skipping this at-par issue as it can be termed a “High Risk-No Return” bet. Read detail review...
Earum Pharmaceuticals Limited
A-1106, Empire Business Hub,
Near AUDA Water Tank, Science City Road,
Sola, Ahmedabad - 380060
Ahmedabad, Gujarat, 380060
The Earum Pharmaceuticals Rights Issue 2023 opens on Tue, May 2, 2023, and closes on Wed, May 31, 2023.
Earum Pharmaceuticals Rights Issue 2023 Schedule
| Last Date for credit of Rights Entitlements | Wed, Apr 26, 2023 |
| Last Date for renunciation of Rights Entitlements | Fri, May 26, 2023 |
| Issue Opening Date | Tue, May 2, 2023 |
| Issue Closing Date | Wed, May 31, 2023 |
| Date of Allotment (on or about) | Tue, Jun 20, 2023 |
| Date of Credit (on or about) | Wed, Jun 21, 2023 |
| Date of Listing (on or about) | Mon, Jun 26, 2023 |
You can apply for Earum Pharmaceuticals Rights Issue 2023 in two ways:
Steps to apply for Earum Pharmaceuticals Rights Issue 2023 using Net Banking (ASBA)
Steps to apply for Earum Pharmaceuticals Rights Issue 2023 using Registrar's website (R-WAP)
